Nanotech and MEMS in Medical Applications: Comprehensive Market and Technology Report Released from MedMarket Diligence


WEBWIRE – Wednesday, July 05, 2006

The most extraordinary possibilities of nanotechnology and MEMS remain to be developed, yet a $billion+ market already exists for these technologies in biomedical applications, spanning cancer treatment, drug delivery, wound management, sensor technologies, pacemakers, molecular diagnostics, hearing aids and others. The current markets, the current status of development and the emerging and potential markets worldwide are detailed in a new report from MedMarket Diligence on the worldwide status of development and market for Micro- and Nanomedicine (see http://www.mediligence.com/rpt-t625.htm.

“The product and market development of nanotechnology and MEMS -- even limited to those in the biomedical field -- cover an incredibly diverse range of technologies, scientific disciplines, products and applications,” says Patrick Driscoll of MedMarket Diligence (MMD). “This has previously precipitated some wildly optimistic forecasts of market potential, but there are in fact many current, commercially established biomedical applications of nanotech and MEMS that are finally grounding some of the potential in reality.”

Currently established MEMS applications include pacemakers, glucose monitoring, biochips (genechips), OTC tests, insulin pumps, nebulizers, needleless injectors, hearing aids, activity monitors, blood bressure, medical flow sensors, and drug delivery systems.

In nanomedicine, current applications include cancer chemotherapy, a new generation of drug delivery systems, wound dressings that exploit the antimicrobial properties of nanocrystalline silver, and others.

The MedMarket Diligence report is an assessment of the products and technologies under development of medical technologies at the nanometer scale and micrometer scale, and an assessment of the market potential for products/technologies to be successfully commercialized for use in clinical practice within a ten year forecast period. The report identifies the technological, market, regulatory or other hurdles to be crossed en route to commercialization. The report provides particular emphasis in detailing the current activities and status of product development at active companies. The report provides a thorough review of the companies active in nanotech and MEMS development, with profiles of over 100 companies. The report details, including table of contents, may be found at http://www.mediligence.com/rpt-t625.htm.

MedMarket Diligence provides tactical decision-making solutions on medical technology to the medical products and investment industries. For additional details, contact Patrick Driscoll at email or call 949-859-3401 or toll-free (in the U.S.) at 1-866-820-1357.



WebWireID16171




Contact Information
Patrick Driscoll
President
MedMarket Diligence, LLC
Contact via E-mail


This news content may be integrated into any legitimate news gathering and publishing effort. Linking is permitted.

News Release Distribution and Press Release Distribution Services Provided by WebWire.